drugset / Trial / NCT01396200

Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine

NCT01396200

Phase 0 Completed 6 enrolled Abramson Cancer Center at Penn Medicine
Non-randomizedParallel-groupTreatment

Summary

The purpose of this study is to determine the feasibility of giving (i) rapamycin or (ii) hydroxychloroquine (HCQ), with standard doses of infusional cyclophosphamide and pulse dexamethasone (cy/dex) for patients with relapsed/refractory multiple myeloma, as well as the feasibility of obtaining multiple blood and bone marrow samples during treatment to assess the pharmacodynamic effects of the treatment.

Timeline

Start
2011-06
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule 600 mg Oral
Subject Hydroxychloroquine Small molecule 800 mg Oral
Subject Sirolimus Small molecule 3 mg Oral
Subject Sirolimus Small molecule 4 mg Oral

Indications